These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 25765698)

  • 1. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial.
    Mfinanga S; Chanda D; Kivuyo SL; Guinness L; Bottomley C; Simms V; Chijoka C; Masasi A; Kimaro G; Ngowi B; Kahwa A; Mwaba P; Harrison TS; Egwaga S; Jaffar S;
    Lancet; 2015 May; 385(9983):2173-82. PubMed ID: 25765698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryptococcal Meningitis Screening and Community-based Early Adherence Support in People With Advanced Human Immunodeficiency Virus Infection Starting Antiretroviral Therapy in Tanzania and Zambia: A Cost-effectiveness Analysis.
    Kimaro GD; Guinness L; Shiri T; Kivuyo S; Chanda D; Bottomley C; Chen T; Kahwa A; Hawkins N; Mwaba P; Mfinanga SG; Harrison TS; Jaffar S; Niessen LW
    Clin Infect Dis; 2020 Apr; 70(8):1652-1657. PubMed ID: 31149704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of antiretroviral therapy and male circumcision after community-based HIV testing and strategies for linkage to care versus standard clinic referral: a multisite, open-label, randomised controlled trial in South Africa and Uganda.
    Barnabas RV; van Rooyen H; Tumwesigye E; Brantley J; Baeten JM; van Heerden A; Turyamureeba B; Joseph P; Krows M; Thomas KK; Schaafsma TT; Hughes JP; Celum C
    Lancet HIV; 2016 May; 3(5):e212-20. PubMed ID: 27126488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The costs of providing antiretroviral therapy services to HIV-infected individuals presenting with advanced HIV disease at public health centres in Dar es Salaam, Tanzania: Findings from a randomised trial evaluating different health care strategies.
    Kimaro GD; Mfinanga S; Simms V; Kivuyo S; Bottomley C; Hawkins N; Harrison TS; Jaffar S; Guinness L;
    PLoS One; 2017; 12(2):e0171917. PubMed ID: 28234969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis.
    Eshun-Wilson I; Okwen MP; Richardson M; Bicanic T
    Cochrane Database Syst Rev; 2018 Jul; 7(7):CD009012. PubMed ID: 30039850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early versus delayed initiation of highly active antiretroviral therapy for HIV-positive adults with newly diagnosed pulmonary tuberculosis (TB-HAART): a prospective, international, randomised, placebo-controlled trial.
    Mfinanga SG; Kirenga BJ; Chanda DM; Mutayoba B; Mthiyane T; Yimer G; Ezechi O; Connolly C; Kapotwe V; Muwonge C; Massaga J; Sinkala E; Kohi W; Lyantumba L; Nyakoojo G; Luwaga H; Doulla B; Mzyece J; Kapata N; Vahedi M; Mwaba P; Egwaga S; Adatu F; Pym A; Joloba M; Rustomjee R; Zumla A; Onyebujoh P
    Lancet Infect Dis; 2014 Jul; 14(7):563-71. PubMed ID: 24810491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cryptococcal antigen prevalence in HIV-infected Tanzanians: a cross-sectional study and evaluation of a point-of-care lateral flow assay.
    Rugemalila J; Maro VP; Kapanda G; Ndaro AJ; Jarvis JN
    Trop Med Int Health; 2013 Sep; 18(9):1075-1079. PubMed ID: 23937699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, randomised controlled trial.
    Mallewa J; Szubert AJ; Mugyenyi P; Chidziva E; Thomason MJ; Chepkorir P; Abongomera G; Baleeta K; Etyang A; Warambwa C; Melly B; Mudzingwa S; Kelly C; Agutu C; Wilkes H; Nkomani S; Musiime V; Lugemwa A; Pett SL; Bwakura-Dangarembizi M; Prendergast AJ; Gibb DM; Walker AS; Berkley JA;
    Lancet HIV; 2018 May; 5(5):e231-e240. PubMed ID: 29653915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory-Reflex Cryptococcal Antigen Screening Is Associated With a Survival Benefit in Tanzania.
    Faini D; Kalinjuma AV; Katende A; Mbwaji G; Mnzava D; Nyuri A; Glass TR; Furrer H; Hatz C; Boulware DR; Letang E
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):205-213. PubMed ID: 30422904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory Reflex and Clinic-Based Point-of-Care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality Among People Living With HIV.
    Drain PK; Galagan SR; Govere S; Krows M; Thulare H; Wallis CL; Gosnell BI; Moosa MY; Celum C; Bassett IV
    J Acquir Immune Defic Syndr; 2021 Aug; 87(5):1205-1213. PubMed ID: 33990495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomised, placebo-controlled trial.
    Parkes-Ratanshi R; Wakeham K; Levin J; Namusoke D; Whitworth J; Coutinho A; Mugisha NK; Grosskurth H; Kamali A; Lalloo DG;
    Lancet Infect Dis; 2011 Dec; 11(12):933-41. PubMed ID: 21982529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV care: ART adherence support and cryptococcal screening.
    Rajasingham R; Boulware DR
    Lancet; 2015 May; 385(9983):2128-9. PubMed ID: 25765697
    [No Abstract]   [Full Text] [Related]  

  • 13. Rates of viral suppression in a cohort of people with stable HIV from two community models of ART delivery versus facility-based HIV care in Lusaka, Zambia: a cluster-randomised, non-inferiority trial nested in the HPTN 071 (PopART) trial.
    Limbada M; Macleod D; Situmbeko V; Muhau E; Shibwela O; Chiti B; Floyd S; Schaap AJ; Hayes R; Fidler S; Ayles H;
    Lancet HIV; 2022 Jan; 9(1):e13-e23. PubMed ID: 34843674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of community health worker-led home delivery of antiretroviral therapy on virological suppression: a non-inferiority cluster-randomized health systems trial in Dar es Salaam, Tanzania.
    Geldsetzer P; Francis JM; Ulenga N; Sando D; Lema IA; Mboggo E; Vaikath M; Koda H; Lwezaula S; Hu J; Noor RA; Olofin I; Larson E; Fawzi W; Bärnighausen T
    BMC Health Serv Res; 2017 Feb; 17(1):160. PubMed ID: 28228134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Community-based antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART): a randomised trial.
    Barnabas RV; Szpiro AA; van Rooyen H; Asiimwe S; Pillay D; Ware NC; Schaafsma TT; Krows ML; van Heerden A; Joseph P; Shahmanesh M; Wyatt MA; Sausi K; Turyamureeba B; Sithole N; Morrison S; Shapiro AE; Roberts DA; Thomas KK; Koole O; Bershteyn A; Ehrenkranz P; Baeten JM; Celum C;
    Lancet Glob Health; 2020 Oct; 8(10):e1305-e1315. PubMed ID: 32971053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV testing and treatment coverage achieved after 4 years across 14 urban and peri-urban communities in Zambia and South Africa: An analysis of findings from the HPTN 071 (PopART) trial.
    Floyd S; Shanaube K; Yang B; Schaap A; Griffith S; Phiri M; Macleod D; Sloot R; Sabapathy K; Bond V; Bock P; Ayles H; Fidler S; Hayes R;
    PLoS Med; 2020 Apr; 17(4):e1003067. PubMed ID: 32240156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitis.
    Njei B; Kongnyuy EJ; Kumar S; Okwen MP; Sankar MJ; Mbuagbaw L
    Cochrane Database Syst Rev; 2013 Feb; (2):CD009012. PubMed ID: 23450595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study.
    Rhein J; Morawski BM; Hullsiek KH; Nabeta HW; Kiggundu R; Tugume L; Musubire A; Akampurira A; Smith KD; Alhadab A; Williams DA; Abassi M; Bahr NC; Velamakanni SS; Fisher J; Nielsen K; Meya DB; Boulware DR;
    Lancet Infect Dis; 2016 Jul; 16(7):809-818. PubMed ID: 26971081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy (REMEMBER): a multicountry open-label randomised controlled trial.
    Hosseinipour MC; Bisson GP; Miyahara S; Sun X; Moses A; Riviere C; Kirui FK; Badal-Faesen S; Lagat D; Nyirenda M; Naidoo K; Hakim J; Mugyenyi P; Henostroza G; Leger PD; Lama JR; Mohapi L; Alave J; Mave V; Veloso VG; Pillay S; Kumarasamy N; Bao J; Hogg E; Jones L; Zolopa A; Kumwenda J; Gupta A;
    Lancet; 2016 Mar; 387(10024):1198-209. PubMed ID: 27025337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating a multi-component, community-based program to improve adherence and retention in care among adolescents living with HIV in Zimbabwe: study protocol for a cluster randomized controlled trial.
    Mavhu W; Willis N; Mufuka J; Mangenah C; Mvududu K; Bernays S; Mangezi W; Apollo T; Araya R; Weiss HA; Cowan FM
    Trials; 2017 Oct; 18(1):478. PubMed ID: 29052529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.